Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI113877

Novel tool for the study of cholecystokinin-stimulated pancreatic enzyme secretion.

H Y Gaisano, U G Klueppelberg, D I Pinon, M A Pfenning, S P Powers, and L J Miller

Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

Find articles by Gaisano, H. in: JCI | PubMed | Google Scholar

Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

Find articles by Klueppelberg, U. in: JCI | PubMed | Google Scholar

Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

Find articles by Pinon, D. in: JCI | PubMed | Google Scholar

Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

Find articles by Pfenning, M. in: JCI | PubMed | Google Scholar

Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

Find articles by Powers, S. in: JCI | PubMed | Google Scholar

Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

Find articles by Miller, L. in: JCI | PubMed | Google Scholar

Published January 1, 1989 - More info

Published in Volume 83, Issue 1 on January 1, 1989
J Clin Invest. 1989;83(1):321–325. https://doi.org/10.1172/JCI113877.
© 1989 The American Society for Clinical Investigation
Published January 1, 1989 - Version history
View PDF
Abstract

The molecular events that mediate cholecystokinin (CCK)-stimulated pancreatic secretion are not well defined because of the complex receptor-binding and concentration-response characteristics of this hormone. Functional models of receptor occupancy initiating the cascade leading to secretion have been complicated by the inhibition of secretion effected by supramaximal concentrations of CCK. Recent report of a CCK analogue that does not exhibit supramaximal inhibition led us to synthesize a similar analogue that could also be radiolabeled for studies of receptor binding and affinity labeling, and for studies of second messenger activity. This probe, D-Tyr-Gly-[(Nle28,31)CCK-26-32]-phenethyl ester, was a fully efficacious secretagogue with no supramaximal inhibition, and, unlike native hormone, bound to a single class of sites present on both acini and membranes. Occupation of this site correlated well with stimulation of secretion. Evidence that this was indeed a CCK-binding site were the abilities of CCK and the antagonist L-364, 718 to inhibit binding of this analogue. Affinity labeling confirmed the identity of the site mediating secretory stimulation as a Mr = 85,000-95,000 protein. Whereas the nonhydrolyzable guanosine triphosphate analogue, 5'-guanylyl-imidodiphosphate, was a potent inhibitor of CCK binding, it had no effect on binding of this secretagogue, suggesting that a novel cascade not involving a guanine nucleotide-binding protein mediates CCK stimulation of pancreatic secretion.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 321
page 321
icon of scanned page 322
page 322
icon of scanned page 323
page 323
icon of scanned page 324
page 324
icon of scanned page 325
page 325
Version history
  • Version 1 (January 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts